USAEUROPEViVE
ABOUTSPONSORSHIPFOUNDATION
Logo Hlth
Logo Hlth
18 Apr 2023 | 02:45 PM GMT

The Potential of OTC DTx Solutions

Anchored by:

Chris Wasden
Chief Strategy Officer
TWILL
Joseph Perekupka
CEO
FREESPIRA, INC

Participants:

Chris Wasden Chief Strategy OfficerTwill
Chris Wasden
Chief Strategy OfficerTwill
Joseph Perekupka CEOFreespira, Inc
Joseph Perekupka
CEOFreespira, Inc
Mette Dyhrberg Founder & CEOMymee
Mette Dyhrberg
Founder & CEOMymee
Anne Muth Market Intelligence ManagerSidekickHealth
Anne Muth
Market Intelligence ManagerSidekickHealth
Arshia Gratiot Founder and CEOEupnoos
Arshia Gratiot
Founder and CEOEupnoos
Christopher Hall Commercial Director, APACMarula Health
Christopher Hall
Commercial Director, APACMarula Health
Gazal Vakili Director, Digital Health InnovationDainippon Sumitomo Pharma
Gazal Vakili
Director, Digital Health InnovationDainippon Sumitomo Pharma
Julie Fishman EIRYale Ventures
Julie Fishman
EIRYale Ventures
Katie Cannon Director - Strategic PartnershipsAvegen Health
Katie Cannon
Director - Strategic PartnershipsAvegen Health
Meredith Kernan Director, Business DevelopmentMass General Brigham
Meredith Kernan
Director, Business DevelopmentMass General Brigham
Mike Pace Founder & CEOPalmHealthCo
Mike Pace
Founder & CEOPalmHealthCo
Nita Thingalaya NA Medical Innovation LeadSanofi
Nita Thingalaya
NA Medical Innovation LeadSanofi
Shwen Gwee Member of the Advisory BoardNew Enterprise Ventures
Shwen Gwee
Member of the Advisory BoardNew Enterprise Ventures

About this Meeting

Small, intimate and participant-led discussions tackling digital health challenges. Spaces are limited to 8 - 12 people, allowing you to focus on quality in-depth conversations.

Curious about what is in store for the future of OTC DTx solutions? Join in the conversation with our expert panel to find out! Over-the-counter (OTC) DTx represents a promising avenue for expanding access to convenient, accessible, and cost-effective treatments. However, challenges including adoption, scaling, integration, and reimbursement structures must be addressed before companies can successfully bring an OTC DTx to market. In this meeting we will discuss the present and future of OTC DTx, including:
  • Market Potential of OTC DTx. What is the current state of play of OTC DTx? What are the main benefits of OTC DTx solutions, and what is the market potential?
  • Navigating the Market. How can companies navigate the space that lacks clear guidelines for approval and reimbursement? When to go traditional pharmaceutical vs. telemedicine prescription pathways?
  • Overcoming Adoption Barriers. How to incentivise HCPs to follow-up and examine data from OTC DTx? Will the prescription of samples/trials (as is done with pharmacologicals) increase HCP adoption?
  • Future Outlook. Where will we see the best potential for growth and innovation? Who is responsible for incentivising stakeholders (i.e pharmacists, HCPs) to adopt OTC DTx? Which areas will see the most investment and development?
We would like to remind you that our meetings are small and intimate sessions with a limited number of seats available, therefore we rely on your attendance and participation to ensure a high quality and valuable meeting for all. If you are confirmed for this meeting we ask if you can please ensure your attendance on the day.